Endo Pharmaceuticals' (ENDP) - Get Report announcement this morning of the promotion of Paul Campanelli to be CEO marks a shift for the company from heavy M&A activity back to its roots as a generic/specialty pharma operating firm, good news for investors who may be tired of more volatile business models made popular by Valeant and to a lesser extent, Endo. Former CEO Rajiv De Silva was previously with Valeant, while new CEO Paul Campanelli was brought over with the Par Pharmaceutical purchase in September 2015.
Another beneficiary of this recent move by Endo may be its much smaller partner, Intellipharmaceutics International (IPCI) , which has a long-standing partnership agreement for the marketing of generic Focalin XR (Dexmethylphenidate hydrochloride extended release), a $760 million in annual sales drug for ADHD.
Endo shares soared more than 15% in Friday trading, while Intellipharmaceutics' price sank over 7%.
IPCI originally signed its deal with Par in 2005 for all dosage strengths of Focalin XR, and while two dosage strengths (15 mg and 30 mg) of the generic were approved by the FDA and launched by Par in November 2013, four more (5, 10, 20 and 40 mg) need additional approval by the agency to meet new regulatory requirements. While IPCI has stated that it is working with Par (now Endo) to obtain the additional approvals, and it is confident Endo will launch as soon as possible, the new emphasis by Endo on operations removes some of the risk of this partnership that may have been perceived after Par was folded into Endo.
What's more, IPCI now may find a more focused potential partner in Endo for other products in its pipeline which have yet be partnered. These include two branded (NDA track) drug candidates, seven additional generic drug ANDA applications, and up to 20 opiate drug candidates with potential for the easier 505(b)(2) regulatory approval route with the FDA.
While ENDP shares responded favorably today to its news release, IPCI shares surged mysteriously yesterday -- so mysteriously IPCI felt it necessary to issue a press release disavowing knowledge of "any corporate developments that may have caused the recent movement in the company's share price". Perhaps, however, the corporate development providing a boost to IPCI came from partner Endo, instead.
This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.